Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors

NCT03420521 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Loss of funding

Conditions

Neuroendocrine Tumors
Carcinoid Tumor

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]